

# Efficacy, tolerability and safety of 0.2% Brimonidine-Tartrate for the treatment of acute non-arteritic anterior ischaemic optic neuropathy

<b>Submission date</b> 12/09/2003	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
<b>Registration date</b> 12/09/2003	<b>Overall study status</b> Completed	<input type="checkbox"/> Protocol
<b>Last Edited</b> 04/04/2016	<b>Condition category</b> Eye Diseases	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Prof I Gottlob

**Contact details**  
University Hospitals of Leicester  
c/o Research and Development Office  
Leicester General Hospital NHS Trust  
Leicester  
United Kingdom  
LE1 4PW  
+44 (0)116 258 4109  
[nicola.turner@uhl-tr.nhs.uk](mailto:nicola.turner@uhl-tr.nhs.uk)

## Additional identifiers

**Protocol serial number**  
N0123109164

## Study information

**Scientific Title**

Efficacy, tolerability and safety of 0.2% Brimonidine-Tartrate for the treatment of acute non-arteritic anterior ischaemic optic neuropathy (NAION): a 3-month, double-masked, randomised and placebo-controlled trial

**Study objectives**

To investigate the effect of this medication which is free from harmful side effects in NAION.

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

Not provided at time of registration

**Study design**

Double-masked randomised and placebo-controlled trial

**Primary study design**

Interventional

**Study type(s)**

Treatment

**Health condition(s) or problem(s) studied**

Eye Diseases: Non-arteritic anterior ischemic optic neuropathy

**Interventions**

Randomised controlled trial

**Intervention Type**

Drug

**Phase**

Not Applicable

**Drug/device/biological/vaccine name(s)**

Brimonidine-Tartrate

**Primary outcome(s)**

Safety of 0.2% Brimonidine-Tartrate for the treatment of acute non-arteritic anterior ischemic optic neuropathy (NAION)

**Key secondary outcome(s)**

Not provided at time of registration

**Completion date**

30/06/2003

**Eligibility**

**Key inclusion criteria**

Patients with acute non-arteritic anterior ischemic optic neuropathy

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Not Specified

**Sex**

Not Specified

**Key exclusion criteria**

Does not match inclusion criteria

**Date of first enrolment**

01/07/2001

**Date of final enrolment**

30/06/2003

**Locations****Countries of recruitment**

United Kingdom

England

**Study participating centre**

University Hospitals of Leicester

Leicester

United Kingdom

LE1 4PW

**Sponsor information****Organisation**

Department of Health (UK)

**Funder(s)**

**Funder type**

Hospital/treatment centre

**Funder Name**

University Hospitals of Leicester NHS Trust (UK)

## Results and Publications

**Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Not provided at time of registration

**Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Participant information sheet</a>	Participant information sheet	11/11/2025	11/11/2025	No	Yes